Background & Aims Tofacitinib, an orally administered Janus kinase inhibitor, blocks
signaling through γ-chain–containing cytokines (interleukins 2, 4, 7, 9, 15, and 21). We …

Conventional systemic and biologic agents are the mainstay of inflammatory bowel disease
(IBD) management; however, many of these agents are associated with loss of clinical …

Background Tofacitinib, a novel, oral Janus kinase inhibitor, demonstrated a dose-
dependent efficacy for induction of clinical response and remission in patients with active …

Background & Aims Tofacitinib is an oral, small molecule inhibitor of JAK for the treatment of
ulcerative colitis (UC). We evaluated the onset of symptom improvement in post-hoc …

Janus kinase/signal transduction and transcriptional activator (JAK/STAT) signaling pathway
is a transport hub for cytokine secretion and exerts its effects. The activation of JAK/STAT …

Prior to the biologic era, the medical management of patients with inflammatory bowel
disease (IBD) was dominated by the use of aminosalicylates, corticosteroids, and …

Background: Although TNF inhibitors revolutionized the therapy of inflammatory bowel
disease (IBD), we have been reaching a point where other therapies with different …

Background & Aims Tofacitinib is an oral, small-molecule Janus kinase inhibitor for the
treatment of ulcerative colitis (UC). We summarize the efficacy and safety data of tofacitinib 5 …

Background & Aims Tofacitinib is an oral, small molecule Janus kinase inhibitor for the
treatment of ulcerative colitis (UC). The efficacy and safety of tofacitinib were demonstrated …

The Janus kinase/signal transduction and activator of transcription (JAK–STAT) signaling
pathway is implicated in the pathogenesis of inflammatory and autoimmune diseases …